

Switch to Bictegravir-Tenofovir alafenamide-Emtricitabine for Black Americans

BRAAVE2020

Switch to Bictegravir-TAF-FTC for Black Americans


BRAAVE2020: Design

- **Background**

- Randomized, phase 3, multicenter, open-label switch study evaluating the efficacy and safety of switching Black American adults with viral suppression to BIC-TAF-FTC, including individuals with a history of NRTI, NNRTI, and/or PI resistance

- **Inclusion Criteria**

- Age ≥ 18 years
- Self-described as Black, African American, or mixed race that includes Black
- HIV RNA < 50 copies/mL for ≥ 12 months
- Taking stable antiretroviral regimen that includes 2 NRTIs plus 3rd agent for ≥ 6 months
- eGFR ≥ 50 mL/min
- No INSTI resistance; no K65R, T69ins, or ≥ 3 TAMs



10% of all participants with M184V at baseline

Switch to Bictegravir-TAF-FTC for Black Americans

BRAAVE2020: Baseline Characteristics

BRAAVE2020 Baseline Participant Demographics & Clinical Characteristics		
Baseline Characteristic	BIC-TAF-FTC (n = 328)	Continue Baseline ART (n = 165)
Age, years, median (range)	49 (18-79)	49 (19-70)
Female sex at birth, n (%)	101 (31)	55 (33)
Cisgender, n (%)	317 (96)	159 (96)
Hispanic or Latino, n (%)	61 (22%)	49 (18%)
CD4 cell count, cells/ μ L, median (IQR)	747 (570-922)	758 (494-969)
TAF-FTC NRTI backbone, n (%)	224 (68)	107 (65)
TDF-FTC NRTI backbone, n (%)	56 (17)	34 (21)
ABC-3TC NRTI backbone, n (%)	44 (13)	24 (15)
Other NRTI backbone, n (%)	4 (1)	0

Source: Hagins D et al. JAIDS. 2021;88:86-95.

Switch to Bictegravir-TAF-FTC for Black Americans


BRAAVE2020: Baseline Characteristics

BRAAVE2020 Baseline Participant Demographics & Clinical Characteristics		
Baseline Characteristic	BIC-TAF-FTC (n = 328)	Continue Baseline ART (n = 165)
Baseline 3 rd agent, n (%)		
INSTI	202 (61)	99 (60)
NNRTI	100 (30)	51 (31)
PI	30 (9)	14 (9)
CCR5 antagonist	0	1 (1)
Baseline ARV resistance, n (%)		
NRTI resistance	44 (13)	26 (16)
M184V/I	31 (9)	20 (12)
NNRTI resistance	70 (21)	32 (19)
PI resistance	36 (11)	26 (16)
INSTI resistance	8 (2)	3(2)

Source: Hagins D et al. JAIDS. 2021;88:86-95.

Switch to Bictegravir-TAF-FTC for Black Americans BRAAVE2020: Results

Week 24 Virologic Response (Intention-to-Treat Analysis)




Primary outcome of HIV RNA ≥ 50 copies/mL at 24 weeks: 0.8% BIC-TAF-FTC arm; 1.6% continue baseline ART arm

Switch to Bictegravir-TAF-FTC for Black Americans

BRAAVE2020: Results

Week 24 Virologic Response by Baseline Resistance (Intention-to-Treat Analysis)



RAM = resistance associated mutation

Switch to Bictegravir-TAF-FTC for Black Americans

BRAAVE2020: Conclusions

Conclusions: “For Black Americans with HIV, switching to B/F/TAF was noninferior to continuing a variety of regimens, including those with pre-existing NRTI mutations.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

